AU2022362077A1 - Treatment of kidney disease - Google Patents
Treatment of kidney disease Download PDFInfo
- Publication number
- AU2022362077A1 AU2022362077A1 AU2022362077A AU2022362077A AU2022362077A1 AU 2022362077 A1 AU2022362077 A1 AU 2022362077A1 AU 2022362077 A AU2022362077 A AU 2022362077A AU 2022362077 A AU2022362077 A AU 2022362077A AU 2022362077 A1 AU2022362077 A1 AU 2022362077A1
- Authority
- AU
- Australia
- Prior art keywords
- patient
- egfr
- approximately
- kidney
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255885P | 2021-10-14 | 2021-10-14 | |
| US63/255,885 | 2021-10-14 | ||
| US202263307801P | 2022-02-08 | 2022-02-08 | |
| US63/307,801 | 2022-02-08 | ||
| US202263321204P | 2022-03-18 | 2022-03-18 | |
| US63/321,204 | 2022-03-18 | ||
| PCT/US2022/078153 WO2023064925A1 (en) | 2021-10-14 | 2022-10-14 | Treatment of kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022362077A1 true AU2022362077A1 (en) | 2024-05-02 |
Family
ID=85988933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022362077A Pending AU2022362077A1 (en) | 2021-10-14 | 2022-10-14 | Treatment of kidney disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250009803A1 (https=) |
| EP (1) | EP4415729A4 (https=) |
| JP (1) | JP2024536479A (https=) |
| KR (1) | KR20240110801A (https=) |
| AU (1) | AU2022362077A1 (https=) |
| CA (1) | CA3233866A1 (https=) |
| MX (1) | MX2024004355A (https=) |
| WO (1) | WO2023064925A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106530A1 (en) * | 2023-11-13 | 2025-05-22 | Butler Emily | Characteristics of enriched heterogeneous renal cell populations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020266168A1 (en) * | 2019-05-02 | 2021-12-02 | ProKidney IPCo, LLC | Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies |
-
2022
- 2022-10-14 AU AU2022362077A patent/AU2022362077A1/en active Pending
- 2022-10-14 US US18/699,849 patent/US20250009803A1/en active Pending
- 2022-10-14 CA CA3233866A patent/CA3233866A1/en active Pending
- 2022-10-14 JP JP2024522027A patent/JP2024536479A/ja active Pending
- 2022-10-14 KR KR1020247015819A patent/KR20240110801A/ko active Pending
- 2022-10-14 MX MX2024004355A patent/MX2024004355A/es unknown
- 2022-10-14 WO PCT/US2022/078153 patent/WO2023064925A1/en not_active Ceased
- 2022-10-14 EP EP22882059.3A patent/EP4415729A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023064925A1 (en) | 2023-04-20 |
| US20250009803A1 (en) | 2025-01-09 |
| JP2024536479A (ja) | 2024-10-04 |
| CA3233866A1 (en) | 2023-04-20 |
| KR20240110801A (ko) | 2024-07-16 |
| EP4415729A4 (en) | 2025-08-27 |
| WO2023064925A8 (en) | 2024-04-11 |
| EP4415729A1 (en) | 2024-08-21 |
| MX2024004355A (es) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12350292B2 (en) | Bioactive renal cells for the treatment of chronic kidney disease | |
| WO2014075589A1 (zh) | 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用 | |
| US20120276067A1 (en) | Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same | |
| US20250268944A1 (en) | Stromal stem cell therapeutics and methods of use | |
| US20070172447A1 (en) | Agent for preventing and/or treating tissue disruption-accompanied diseases | |
| US20250009803A1 (en) | Treatment of kidney disease | |
| EP3490570A1 (en) | Bioactive renal cells for the treatment of chronic kidney disease | |
| CN118354777A (zh) | 肾脏疾病的治疗 | |
| HK40113884A (zh) | 肾脏疾病的治疗 | |
| Seeley et al. | Suspected COVID-19 immunization-induced probable catastrophic antiphospholipid syndrome | |
| Schmid et al. | New strategies for managing anemia of chronic kidney disease | |
| CN114350607B (zh) | 骨髓来源的成熟b细胞及其在制备治疗心肌梗死的药物中的应用 | |
| Gariani et al. | Impact of Islet Transplantation on Type 1 Diabetes-Related Complication: A Systematic Review | |
| TWI780431B (zh) | 新穎性醫藥組合物及其於修復肝臟損傷、治療肝臟損傷相關疾病與提升肝臟功能之用途 | |
| Parlatır et al. | Effect of Intravenous Adipose Tissue-Derived Mesenchymal Stem Cell Administration on Glycemic Index in a Cat with Diabetes Mellitus | |
| EP4146235A1 (en) | Methods for treating coronavirus disease | |
| Simu et al. | ISCHEMIC STROKE IN SYSTEMIC LUPUS ERYTHEMATOSUS-A CASE REPORT. | |
| Hillyer | Morbidity and mortality in adults with idiopathic thrombocytopenic purpura: JFA Portielje, RGI Westendorp, HC Kluin-Nelemans, et al. Blood 97: 2549–2554, 2001 | |
| Kröpfl | E-mail: christina. spengler@ hest. ethz. ch | |
| Martini et al. | Therapeutic applications of stem cells obtained from peripheral blood in tendons, ligaments and skin injuries | |
| Kutsogiannis | Donor Organ Management: Literature Review | |
| Avades | Renal Effects of X-ray Contrast Media in Different Experimental Models | |
| Fridell et al. | Mini-Orals: Clinical Pancreas and Islet Transplantation | |
| Lundgren | Evaluation of strategies to predict and improve early graft survival in clinical islet transpalntation | |
| Sampaio et al. | Detection and Monitoring of Cytomegalovirus Infection, Human Herpesvirus-6 and Human Herpesvirus-7 in Liver Transplantation: Clinical Correlation Laboratory.: Abstract# P-365 |